Payment overview · 2025
General Payments
$707.49
36 reported records · 15 companies
Healthcare provider profile · identity verified
Gary Matthew Fowler, MD
Allopathic & Osteopathic Physicians|Family Medicine · WINFIELD, AL · NPI 1073503405
Verified facts
What the public records show
CMS Open Payments records show Gary Matthew Fowler, MD received $707.49 in general payments during 2025 across 36 reported records.
Sumitomo Pharma America, Inc. accounted for 33.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 276 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $238.00 | 33.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $97.64 | 13.8% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.83 | 11.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $50.68 | 7.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.77 | 6.9% | 3 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $33.85 | 4.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $29.99 | 4.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.17 | 2.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.98 | 2.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.72 | 2.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.05 | 2.4% | 1 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.19 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.29 | 2.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.56 | 1.9% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $7.77 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $707.49 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $238.00 | 9 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $82.83 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $55.83 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.77 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.81 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.47 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.99 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.98 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.72 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $7.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 276 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 168 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
276 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
168 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 997 | 147 |
| Atorvastatin Calcium | Atorvastatin Calcium | 705 | 167 |
| Omeprazole | Omeprazole | 490 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 432 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 410 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 389 | 102 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 389 | 98 |
| Furosemide | Furosemide | 354 | 88 |
| Tramadol Hcl | Tramadol Hcl | 326 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 325 | 136 |
| Potassium Chloride | Potassium Chloride | 319 | 81 |
| Losartan Potassium | Losartan Potassium | 313 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 295 | 86 |
| Eliquis | Apixaban | 295 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 290 | 71 |
| Farxiga | Dapagliflozin Propanediol | 276 | 62 |
| Sertraline Hcl | Sertraline Hcl | 248 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 246 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 243 | 54 |
| Montelukast Sodium | Montelukast Sodium | 240 | 72 |
| Clonazepam | Clonazepam | 228 | 29 |
| Glipizide Er | Glipizide | 225 | 61 |
| Metformin Hcl | Metformin Hcl | 224 | 60 |
| Lisinopril | Lisinopril | 223 | 67 |
| Famotidine | Famotidine | 214 | 73 |
| Donepezil Hcl | Donepezil Hcl | 199 | 50 |
| Lovastatin | Lovastatin | 193 | 50 |
| Meloxicam | Meloxicam | 192 | 52 |
| Pregabalin | Pregabalin | 178 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 177 | 47 |
| Trazodone Hcl | Trazodone Hcl | 177 | 42 |
| Metformin Hcl Er | Metformin Hcl | 175 | 49 |
| Jardiance | Empagliflozin | 168 | 33 |
| Buspirone Hcl | Buspirone Hcl | 160 | 35 |
| Carvedilol | Carvedilol | 153 | 42 |
| Methocarbamol | Methocarbamol | 152 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 150 | 19 |
| Alprazolam | Alprazolam | 141 | 17 |
| Mirtazapine | Mirtazapine | 136 | 35 |
| Allopurinol | Allopurinol | 131 | 36 |
| Alendronate Sodium | Alendronate Sodium | 128 | 41 |
| Memantine Hcl | Memantine Hcl | 123 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 122 | 31 |
| Fenofibrate | Fenofibrate | 122 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 119 | 33 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 118 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 25 |
| Trulicity | Dulaglutide | 109 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 104 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 99 | 23 |
| Celecoxib | Celecoxib | 98 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 93 | 24 |
| Simvastatin | Simvastatin | 93 | 26 |
| Chlorthalidone | Chlorthalidone | 91 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 20 |
| Januvia | Sitagliptin Phosphate | 84 | 11 |
| Finasteride | Finasteride | 82 | 19 |
| Ozempic | Semaglutide | 81 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 81 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 30 |
| Xarelto | Rivaroxaban | 80 | 19 |
| Spironolactone | Spironolactone | 79 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 76 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 76 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 76 | 21 |
| Lorazepam | Lorazepam | 75 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 21 |
| Myrbetriq | Mirabegron | 65 | 15 |
| Synthroid | Levothyroxine Sodium | 64 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 64 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 63 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 16 |
| Sucralfate | Sucralfate | 60 | 20 |
| Temazepam | Temazepam | 59 | suppressed |
| Baclofen | Baclofen | 57 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 55 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 54 | 12 |
| Estradiol | Estradiol | 53 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 15 |
| Atenolol | Atenolol | 49 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 48 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 34 |
| Ezetimibe | Ezetimibe | 43 | 14 |
| Fosinopril Sodium | Fosinopril Sodium | 43 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 37 |
| Topiramate | Topiramate | 42 | 13 |
| Amoxicillin | Amoxicillin | 40 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 25 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | 14 |
| Dapagliflozin | Dapagliflozin Propanediol | 37 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | 12 |
| Primidone | Primidone | 37 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 35 | suppressed |
| Mounjaro | Tirzepatide | 35 | 16 |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Glipizide | Glipizide | 33 | 11 |
| Ramipril | Ramipril | 33 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 31 | 30 |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 16 |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Cefdinir | Cefdinir | 28 | 25 |
| Nabumetone | Nabumetone | 28 | 11 |
| Nystatin | Nystatin | 28 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Verapamil Er | Verapamil Hcl | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Glimepiride | Glimepiride | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 15 |
| Azithromycin | Azithromycin | 25 | 25 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Methadone Hcl | Methadone Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Premarin | Estrogens, Conjugated | 23 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | 14 |
| Rivastigmine | Rivastigmine | 21 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Invokana | Canagliflozin | 17 | suppressed |
| Lacosamide | Lacosamide | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 14 |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $707.49 · 36 records | Sumitomo Pharma America, Inc. | Auvelity, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, Flector, GEMTESA, IBSRELA, JARDIANCE, Kerendia, Korlym, Licart, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, Ozempic, REPATHA, TOLMETIN SODIUM, Tirosint, VRAYLAR, Wegovy, XIFAXAN | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error